Index

Alpha-thalassemia
carrier frequency among African Americans, 260
carrier screening for, 15, 231, 260
genetics of, 260
incidence among Asian newborns of, 260
stillbirths in Southeast Asia due to, 260

Abortion
cost of, 218
cost-effectiveness and assumptions about, 39-40, 213, 219, 224
effect on cost-effectiveness of, 40, 223-224
genetic counseling and, 45, 127
prenatal diagnosis of genetic disorders and attitudes toward, 28-29, 127, 190, 219, 265
role in controversy over CF carrier screening, 15, 16, 60
Supreme court rulings on, 45, 127

Accreditation, 112-113

Adenosine deaminase deficiency, gene therapy for, 94

Adrenoleukodystrophy, health insurance difficulties and, 34, 200

Adult polycystic kidney disease (APKD)
health insurance difficulties and, 34, 200
inheritance pattern of, 87
risk comprehension in families affected by, 143

Adverse selection
genetic tests and potential for, 178
health insurance and, 174

African Americans
beta-thalassemia mutations in, 259
CF carrier frequency among, 14, 145
frequency of alpha-thalassemia carriers among, 260
frequency of CF live births among, 5, 49, 90, 219
frequency of sickle cell anemia and trait in, 258
frequency of sickle cell anemia live births among, 258
frequency of sickle cell carriers, 258
government interest in addressing sickle cell anemia among, 15, 51-52
see also Asian Americans; Caucasian Americans of European descent; Hispanic Americans

Agency for Health Care Policy and Research-DHHS, 43
Alabama
disability statute of, 204
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Alaska
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Albania, frequency of AF508 in, 248
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), CF-related research funded by, 101, 102
Alcoholics, compulsory sterilization and, 51
Allele specific oligonucleotide (ASO) probes, 11, 95, 96, 98
Alpha-1 antitrypsin deficiency
genetic therapy and, 6, 76
health insurance difficulties and, 34, 200
Alpha-fetoprotein. See Maternal serum alpha-fetoprotein
American Academy of Pediatrics (AAP), 119, 144
American Association of BioAnalysts, CLIA accreditation and, 113
American Board of Medical Genetics (ABMG)
certification by, 24, 121
genetic counselors’ certification and, 4, 23, 50, 121, 152
American Caucasians of European descent. See Caucasian Americans of European descent
American College of Medical Genetics, 123
American College of Obstetricians and Gynecologists (ACOG) policy statement on CF carrier screening of, 231
policy statement on MSAFP screening of, 144
regulation of MSAFP test kits and, 119
American Medical Association (AMA)
codes of ethics and, 123
policy statement on CF carrier screening of, 123
American Osteopathic Association, CLLA accreditation and, 113
American Society of Human Genetics (ASHG)
MSAFP screening and, 144
policy statement on reproductive options, 127
role in 1975 NRC report, 54
role in proficiency testing of, 36, 115
Americans With Disabilities Act of 1990 (ADA)
as a focus of congressional options to address genetic discrimination, 42
definition of disability under, 33-34, 204
health insurance and, 35, 42, 206-207
relevance to genetics of, 34-35, 51, 202, 205-206
Amiloride, 6, 76

Amniocentesis
prenatal diagnosis using, 147
reimbursement under Medicaid for, 28, 182-184

Amplification refractory mutation system (ARMS) multiplex kit, 116, 233, 234

Arabs, sickle cell mutation in, 258

Arizona
genetic services funding in, 159
hereditary conditions and state law in, 202
Medicaid program in, 182

Arkansas
genetic services funding in, 159

Asian Indians, sickle cell mutations in, 258

Association of Schools of Public Health, 155

Australia
cf screening of newborns in, 73
memorandum in European Concerted Action on Cystic Fibrosis of, 241

Austria
carrier screening pilot study in, 17, 238, 239

memorandum in European Concerted Action on Cystic Fibrosis of, 241

Automation
affect on costs of, 37, 44
as a factor affecting utilization of CF carrier tests, 20, 37-38
congressional options to address, 40, 43

Human Genome Project funding of, 37, 99
impact on CF carrier screening of, 100

of DNA diagnostic procedures, 98-100

β-thalassemia
carrier screening for, 15, 261-263
congressional interest in, 52, 259, 261
etnic populations affected by, 259, 260
genetics of, 88, 260-261
manifestations of, 259-260
State law against discrimination for, 202

Base case, assumptions used in cost-effectiveness, 39, 220-221

Baylor College of Medicine
case of health insurance difficulties and CF prenatal screening, 33, 200
cost of CF mutation analysis at, 39, 216
privately funded pilot study at, 19, 161

Belgium
frequency of ΔF508 in, 248
density of ΔF508 in Antwerp, 248

memorandum in European Concerted Action on Cystic Fibrosis of, 241

Biomedical Ethics Advisory Committee, U.S. congressional, 205

Blastomere analysis before implantation (BAB1), prenatal analysis using, 147-148

Blindness, compulsory sterilization and, 51

Blue Cross/Blue Shield (BC/BS) plans

attitude toward carrier status as preexisting conditions of, 31, 195
attitude toward fairness in using genetic tests of, 177
attitude toward genetic conditions as preexisting conditions of, 31, 195
attitude toward medical information versus genetic information of, 31, 195
attitude toward option of using genetic information of, 177-178
demographics of respondents, 176-177

factors affecting insurability by, 31-32, 195-196
future use of genetic tests by, 32, 197-199
impact of genetic tests on, 32-33, 178
open enrollment under, 171, 172
regulation of, 25, 171
reimbursement for CF carrier tests by, 27, 181
reimbursement of genetic counseling by, 28, 182
structure of, 170-171

see also Commercial health insurers; Health insurance; Health insurers; Health maintenance organizations

Boston University, cost of CF mutation analysis at, 39, 216

Bulgaria
frequency of ΔF508 in, 248

memorandum in European Concerted Action on Cystic Fibrosis of, 241

Bureau of Health Care Delivery and Assistance—DHHS, support for genetics education of nurses by, 155

Bureau of Maternal and Child Health and Resources Development—DHHS, genetics professional education and training support by, 154

California
α-thalassemia carrier screening in, 260
court ruling on Tay-Sachs carrier screening and standard of care, 121-122
genetic services funding in, 159
hereditary conditions and state law in, 202, 203
Hereditary Disorders Act of 1990, 203
licensing and regulations for DNA laboratories in, 36, 114
Medicaid reimbursement for genetic services in, 183
MSAFP screening in, 151
non-master’s-level counselors and sickle cell programs in, 155

prenatal screening fees as a source of genetic services finding in, 26, 53
reproductive stipmatization and Bree Walker Lampley in, 29, 191

Tay-Sachs carrier screening of Orthodox Jews in, 256

wrongful life claims in, 130

Canada
β-thalassemia carrier screening in, 261
CF carrier screening in, 29, 150, 162, 191-192
ELSI grant to survey views of genetic specialists in, 55
frequency of ΔF508 in, 191, 247, 253

median CF survival data from, 6, 77

Tay-Sachs carrier screening in, 254, 255, 256, 257

Tay-Sachs carrier screening of Orthodox Jews in Montreal, 256

Caregiving, costs of, 38, 215-216

Carrier. See Carrier screening; Carrier status; Cystic fibrosis carrier screening

Carrier screening
definition used in OTA report of, 4, 50
for β-thalassemia, 259-263
for sickle cell trait, 258-259
for Tay-Sachs, 255-257
goals of, 57
value of, 45, 54, 213-214, 226
see also Cystic fibrosis carrier screening

Carrier status
ADA and, 35, 205, 206
frequency among Caucasians of positive CF, 3, 10, 58, 90
health insurers’ attitudes toward, 31, 195, 200
number of Americans with positive CF, 8, 49, 90
stigmatization of, 28-29, 189-192

Carrier testing
definition used in OTA report of, 4, 50
see also Cystic fibrosis carrier testing

Caucasian Americans of European descent
carrier frequency of CF among, 14, 58, 90, 121, 145
carrier frequency of Tay-Sachs disease among, 121
carrier frequency of CF live births among, 5, 49, 90, 121
see also African Americans; Asian Americans; Hispanic Americans

Cellmark Diagnostics, U.K.
development of CF mutation analysis kit, 116
U.K. pilot programs and use of CF mutation analysis test kit
of, 233, 234
Centers for Disease Control, 119
Certification
of genetic specialists, 23, 120-121
see also Licensing
Cetus Corp., 217
Chest physical therapy (PT)
cost of, 216
elements of, 76
time devoted to, 38, 216
Chevra Dor Yeshorim, 256
Children’s Hospital Oakland Research Institute, NIH-funded
pilot study at, 18, 157
China
-4- thalassemia carrier screening in, 260
-4- thalassemia carrier screening in, 262-263
-5- thalassemia mutations in, 259
Chloride ion (Cl-), concentration as an indicator of CF, 9, 72
Chorionic villus sampling (CVS)
cost of, 218
Prenatal diagnosis of CF using, 147
reimbursement under Medicaid for, 28, 182-184
Chromosome
number 7-6, 8, 58, 90
structure and organization in humans, 6, 7, 58, 85, 87
translocations and health insurance difficulties, 200
Chromosome analysis, reimbursement under Medicaid for, 28,
182-184
Civil Rights Act, relevance to genetics of Title VII of the, 51, 202
Civilian Health and Medical Program of the Uniformed Services
(CHAMPUS), health care coverage under, 25, 170
Clinical laboratories
congressional options for regulation of, 40, 42
regulation of 35-37, 111-116
see also Clinical Laboratory Improvement Amendments of 1988
Clinical Laboratory Improvement Amendments of 1988 (CLIA)
accreditation under, 36, 112-113
congressional options for, 42
DNA tests and impact of, 36, 114, 132
facilities covered by, 36, 112, 113
monitoring laboratory performance under, 113
professional societies and, 36, 114-116
proficiency testing requirements of, 37, 113, 114
regulatory requirements as a function of complexity under,
112
sanctions under, 112, 113-114
State authorities under, 36, 113, 114
Collaborative Research, Inc., cost of CF mutation analysis by,
39, 216
College of American Pathologists (CAP)
CLIA accreditation and, 36, 113
DNA-based test proficiency pilot studies of, 36, 115
Colorado
CF screening of newborns in, 4, 50, 73
Genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
newborn screening fees as a source of genetic services funding
in, 26, 53
Commercial health insurers
1991 OTA survey of, 27, 28, 31-33, 62, 194-195
attitude toward carrier status as preexisting conditions of, 31,
195
attitude toward fairness in using genetic tests of, 32-33, 177
attitude toward genetic conditions as preexisting conditions
of, 31, 195
attitude toward medical information versus genetic informa-
tion of, 31, 195
attitude toward option of using genetic information of,
177-178
demographics of respondents, 176-177
factors affecting insurability by, 31-32, 195-196
future use of genetic tests by, 32, 197-199
impact of genetic tests on, 32-33, 178
regulation of, 25, 175
reimbursement for CF carrier tests by, 27, 180-181
reimbursement of genetic counseling by, 27, 182
see also Blue Cross/Blue Shield plans; Health insurance;
Health insurers; Health maintenance organizations
Confidentiality
as duty in genetic counseling, 22-23, 128-129
breach of, 22, 23, 131, 148
codes of ethics and, 128
conditions identified by 1983 President’s Commission report
that override, 128-129
ELSI grants funded that relate to, 55-56
inductive screening and, 148
States’ roles in protecting, 22, 128
Congress, U.S.
clinical laboratory regulation and, 35-37, 111-113
Human Genome Project and, 3, 54
interest in genetics and public health of, 51-52
issues and options for, 40-45
President’s Commission for the Study of Ethical Problems in
Medicine and Biomedical and Behavioral Research and,
52, 54
see also General Accounting Office; House Committee on
Energy and Commerce; House Committee on Science,
Space, and Technology; Office of Technology Assessment
Connecticut
Genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Consumers
Concerns about health insurance of, 29-30, 192, 194, 200-201
interest in CF carrier screening of, 20-21, 121
perceptions of genetic risk by, 24, 142-143
Cooley’s anemia. See $\beta$-thalassemia
Cordocentesis, prenatal analysis using, 147
Cornell University Medical College
cost of CF mutation analysis at, 39, 216
privately funded pilot study at, 19, 161
Cost-effectiveness
as a factor affecting utilization of CF carrier tests, 20, 38-40
caveats about, 38, 213-214, 224-226
effect of assumptions on, 40, 222-224
variables and assumptions used in analysis of, 3940, 218-220
Cost offsets, calculation of, 222
costs
as a factor affecting utilization of CF carrier tests, 20, 38-40
calculation of base case and alternative scenario, 220-222
CF-related nonmedical (caregiving), 38, 215-216
components of CF-related medical, 38, 214-215
not included in OTA analysis, 214
of CF carrier screening in the general population, 216-218
of CF mutation analysis, 39, 60, 216
of CF treatment in the United Kingdom, 231
range of CF-related medical, 38, 215
with no carrier screening, 220
Council of Regional Networks for Genetic Services (CORN)
DNA-based test proficiency pilot studies of, 36, 115
Federal funding for, 25, 26, 36, 53, 154
Courts, role in ensuring quality of genetic services of, 21, 23,
111, 124, 129
Coverage. See Reimbursement; Health insurance
Cuba, membership in European Concerted Action on Cystic
Fibrosis of, 241
Customary physician practice. See Standards of care
Cyprus, β-thalassemia carrier screening program in, 262
Cystic fibrosis (CF)
ADA and, 34-35, 205
age distribution of individuals with, 7, 77-78
births annually, 3, 49
births to couples with no family history, 3, 50, 61
chest physical therapy for, 76
costs of, 38, 214-215
diagnosis of, 4, 72-73
gene therapy for, 5, 6, 76, 94
ge genetics of, 8-9, 90-94
health insurance difficulties and, 33, 34, 79, 200
history of, 49
in the United Kingdom, 231-232
incidence among American newborns of, 5, 49, 69, 90
inheritance pattern of, 3, 6, 8, 50, 88, 90
life insurance and, 176
median survival, 5, 6, 77
medical management of, 73-76
number of people in the United States with, 3, 49
number of potential carriers in the United States for, 8, 49, 90
organ systems affected by, 3, 4, 5-7, 90
pathology of, 4, 69, 72
pharmaceuticals used to treat, 74, 75, 76
prenatal diagnosis of, 147-148
prognosis, 4, 5, 6, 7, 77-78
psychological aspects, 6, 78-79
research funding for, 3-4, 100-103
risk to carrier couples of having a child with, 10, 59
risks to detect, 72-73
treatment for, 5, 6, 73-77
wrongful birth claim for, 130
Cystic fibrosis carrier screening
ability to self-pay and access to, 27, 121
anxiety and, 148, 151
congressional issues and options for, 40-45
discussion surrounding, 11, 14-15, 56-61
cost-effectiveness of, 39-40, 218-226
costs of, 39, 216-218
couples approach to, 17, 236
definition used in OTA report of, 4, 10, 50
discrimination issues of, 14, 60, 189-207
distinction between CF carrier testing and, 4, 50
education issues for, 24, 149-150
future implications of, 43-45
genetic counseling scenario for, 145-150
goals of, 57
in the United Kingdom, 17, 231-242
in the United Kingdom compared to the United States, 17,
231, 232, 241-242
insurability and, 31-32, 195-196
lessons from other genetic screening programs for, 15, 16, 24,
143, 144, 151-152, 263-265
medical malpractice and, 20-21, 23, 122, 123, 129-131
number of individuals potentially involved in, 16, 58
opposition to, 14-15, 59, 60, 61, 121, 122-124
population targets, 16, 58, 150-152, 157-158, 160-163, 239
preexisting conditions and, 31, 195
pressures for and against, 11, 14, 15, 56-61
psychological aspects of, 141
quality assurance of, 35-37, 60-61, 111-132
reimbursement for, 27-28, 179-182
sensitivity of detection of, 10-11, 13-14, 58-59, 146-147
setting for, 25, 145
standards of care and, 20-21, 121-124
support for, 15, 59-60, 61, 124
technologies used in, 12, 95-100
trends, 17-18, 20, 61
utilization of, 18, 20, 61
value of, 45, 54, 213, 214, 226
see also Cystic fibrosis carrier tests
Cystic fibrosis carrier testing
definition used in OTA report of, 4, 50
distinction between CF carrier screening and, 4, 50
Cystic fibrosis carrier tests
accuracy of, 10, 58
automated of, 37-38, 98-100
based on function of CFTR, 9, 93
cost of, 39, 60, 216, 225
development and regulation of kits for, 37, 116-120
development in, 12, 95-100
limits of, 10, 98
number of, 9-10, 18, 20, 61
number of facilities performing, 61, 216
reimbursement for, 27, 179-182
risk of child with CF after using, 11, 13, 59, 146-147
sensitivity of, 10-11, 13-14, 58-59, 146
use of mouthwash samples for, 17, 231
see also Cystic fibrosis carrier testing; Cystic fibrosis
mutation analysis
Cystic fibrosis centers
estimate of CF-related caregiving time by, 215-216
specialized treatment at, 73, 74
Cystic Fibrosis Foundation (CFF)—United States
acceptance of DNA analysis as positive diagnosis by, 73
carrier screening and, 16, 52, 60
clinical centers of, 73, 74
collaboration with NIH to fund research of, 102, 103
cost estimates based on data from, 214-215
data collection through annual survey by, 73, 129
decision to conduct research of, 5
estimate of median lifespan by, 73
research funded by, 100, 101, 103
Cystic fibrosis gene localization of, 3, 6, 8, 91
mutations in, 9, 58, 91
product of, 8, 91, 93
structure of, 8-9, 91, 92
Cystic Fibrosis Genetic Analysis Consortium-North America, 241, 247
Cystic fibrosis mutation analysis
development and regulation of kits for, 37, 116-120
diagnostic use of, 73,99
DNA techniques used in, 12,95-100
pretest education about, 141-142
reimbursement for, 112-116
risk of child with CF after, 146-147
sensitivity of, 10-11, 13-14, 58-59, 146
testing relatives and, 145-146, 148
see also Cystic fibrosis carrier screening; Cystic fibrosis carrier tests
Cystic fibrosis mutations
automated detection of, 37-38, 99, 100
correlation with prognosis, 9, 91
DNA technologies to detect, 12,95-100
frequency among African Americans, 14, 145
frequency among American Caucasians of, 14, 90, 145, 253
frequency among Asian Americans, 14, 145
frequency among Hispanic Americans, 14, 145
frequency in Europe of, 10,247-253
international variation, 9, 10, 246-253
number of, 9, 58, 91
see also specific mutations
Cystic Fibrosis Research Trust (CF Trust)-United Kingdom
CF carrier screening pilot programs funded by, 17, 231, 233-238
role in CF carrier screening of, 16, 233
Cystic fibrosis screening
definition used in OTA report of, 4,50
see also Newborn screening
Cystic fibrosis testing
definition used in OTA report of, 4,50
see also Newborn screening
Cystic fibrosis transmembrane conductance regulator (CFTR)
effect of mutation on, 9, 91, 93
function of, 9,91, 93
structure of, 92
Czech and Slovak Federal Republic
frequency of AF508 in, 248
frequency of AF508 in Bohemia/Moravia, 248
frequency of AF508 in Slovakia, 248
membership in European Concerted Action on Cystic Fibrosis of, 241
Czechoslovakia (former). See Czech and Slovak Federal Republic
Darwin, Charles, 51
Deafness, compulsory sterilization and, 51
Defensive medicine. See Medical malpractice
Definitions, used in OTA report, 4,49-50
Delaware
 genetic services funding in, 159
 genomics education, technical assistance, and training funding in, 160
 Medicaid reimbursement for genetic services in, 183
CF carrier screening in, 17, 238,239
frequency of AF508 in, 248
homogeneity of AF508 in, 247
membership in European Concerted Action on Cystic Fibrosis of, 241
Deoxyribonucleic acid (DNA)
function and organization of, 85
proteins and, 86
replication of, 85-86, 88,97
structure of, 7, 85, 86
see also DNA tests
Department of Defense, U.S. (DOD), 170
Department of Energy, U.S. (DOE)
ELSI Program of, 5,55-56
Human Genome Project funding by, 101
Joint Subcommittee on the Human Genome (ND-I) of, 35,206
public education grant funded by ELSI Program of, 24, 149-150
Department of Health and Human Services, U.S. (DHHS),112, 154
AF508
automated detection of, 99
detection of, 9,91-99
frequency in Caucasian Americans of, 9,58,91, 146
homogeneous occurrence in Denmark of, 247
occurrence in Europe of, 13-14, 247-252, 253
percent of carrier couples detected by, 146
percent of CF carriers detected with test for, 9, 10,247
severity of, 91
Diabetes, CF-associated, 71
Diagnosis
of β-thalassemia, 261
of CF, 4, 72-73
of sickle cell anemia, 258
of Tay-Sachs disease, 254-255
Digestive therapy, 75
Disability
definition under the ADA of, 33-34,204-205
Medicare coverage and, 169
State law and, 204
stigmatization of, 16, 29, 189-191
Discrimination
ADA and genetic, 34-35,51,202,205-206
as a factor affecting utilization of CF carrier tests, 20, 28-35
concerns stemming from CF carrier screening, 28-35,60
congressional options to address genetic, 40, 42
definition of, 189
sickle cell screening and, 259
U.S. law and genetic, 33-35,202-207
see also Stigmatization
District of Columbia
disability law in, 204
stigmatization of, 16, 29, 189-191
Discrimination
ADA and genetic, 34-35,51,202,205-206
as a factor affecting utilization of CF carrier tests, 20, 28-35
concerns stemming from CF carrier screening, 28-35,60
congressional options to address genetic, 40, 42
definition of, 189
sickle cell screening and, 259
U.S. law and genetic, 33-35,202-207
see also Stigmatization
District of Columbia
disability law in, 204
stigmatization of, 16, 29, 189-191
Discrimination
ADA and genetic, 34-35,51,202,205-206
as a factor affecting utilization of CF carrier tests, 20, 28-35
concerns stemming from CF carrier screening, 28-35,60
congressional options to address genetic, 40, 42
definition of, 189
sickle cell screening and, 259
U.S. law and genetic, 33-35,202-207
see also Stigmatization
DNA, See Deoxyribonucleic acid
DNA sequencing, 98-100
DNA tests
CLIA impact on, 36, 114, 132
diagnosis of CF using, 4,73
impact of intellectual property protection on utilization of, 44, 217
regulation of clinical laboratories performing, 35-37, 112-116
regulation of kits for, 37, 116-120
reimbursement under Medicaid for, 28, 182-184
techniques used in, 95-100
see also Cystic fibrosis mutation analysis; Tests
DNase, 6, 76
Dot blot, 12, 95, 96, 98
Dot blot, reverse, 12, 98, 99
Down syndrome
health insurance difficulties and, 34, 200
MSAFP screening and, 16, 143, 144
Drugs. See Pharmaceuticals
Duchenne muscular dystrophy, inheritance pattern of, 88

East Germany (former). See Germany

Economic considerations

costs of CF, 38, 214-218
costs of CF carrier screening, 39, 216-218
genetic tests and health insurers' evaluation of, 32-33, 178-179
human capital approach, 214
pressure to screen stemming from, 14, 60
see also Cost-effectiveness; Costs; Financing; Reimbursement

Ectodactyly, 29, 191

Education
average medical school curriculum for genetics, 25, 151
congressional issues and options for professional training and, 40, 4142
congressional issues and options for public, 40-41
cost of pretest, 217-218
ELSI grants funded that relate to, 55-56
of genetic specialists, 25, 152, 153-154
of health care professionals, 25, 151, 155
of public, 15, 24, 149-150
pretest, 141-142, 224-225
SPRANS funding for, 26, 53, 160

Electrophoresis, 12, 95, 96, 99

Employee Retirement Income Security Act of 1974 (ERISA)
exemption from State insurance regulation under, 27, 171
health care benefits under, 194
health care plans under, 27, 171
OTA workshop on genetic tests and, 276
relationship to ADA of, 35, 42, 194
see also Self-funded employers

England
frequency of AF508 in, 231, 252
membership in European Concerted Action on Cystic Fibrosis of, 241
Tay-Sachs carrier screening in, 255
see also United Kingdom

Epidemiology
of AF508 in Europe, 10, 247-252
of AF508 in North American subpopulations, 253
of mutations for CF, 91, 247-253
of mutations for CF in Europe versus North America, 253

Equal Employment Opportunity Co remission, U.S. (EEOC),
genetics and regulations implementing the ADA of, 35, 205, 206

Ethical considerations
ELSI grants funded that relate to, 55-56
of gene therapy, 94
of genetics and health insurance, 193
OTA report and, 62

Ethical, Legal, and Social Issues (ELSI) Program-DOE as a focus of congressional options to enhance professional education and training, 42
as a focus of congressional options to improve public education in genetics, 41
grants funded by, 56-56
public education grant funded by ELSI, 149-150
total funding for, 5, 55

Ethical, Legal, and Social Issues Working Group-NII-I/DOE

Eti-Turks, sickle cell mutation in, 258

Eugenics
history of, 51
public health goals of genetic screening and potential perception of, 57

Europe
automation of DNA analysis in, 100
frequency of CF mutations in, 9-10, 247-253
Tay-Sachs carrier screening of Orthodox Jews in, 256
see also specific countries
European Concerted Action on Cystic Fibrosis, 241, 247
European Working Group on Cystic Fibrosis, 247

Exocrine glands, effect of CF on, 69

Fabry disease, health insurance difficulties and, 34, 200
Fair Housing Amendments Act of 1988, 202, 204

Family history
CF carrier risk after negative test when positive, 146
CF carrier risk when positive, 145
likelihood of reimbursement for CF mutation tests with positive, 27-28, 180, 181

Federal Bureau of Investigation, 55
Federal Communications Commission (FCC), 29, 191
Federal Fair Credit Reporting Act, 175
Federal Food, Drug, and Cosmetic Act of 1938, 116
Federal Government
funding for genetic services by, 25, 26, 52-53, 158-160
genetics and, 16, 51-56, 155-160, 202, 203-207
regulation of clinical laboratories by, 35-37, 111-116
regulation of medical devices by, 37, 116-120
see also individual agencies

Financing
as a factor affecting utilization of CF carrier tests, 20, 25, 27
private, 25, 27, 170-174
public, 25, 169

Finland, frequency of AF508 in, 248

Florida
geneic services funding in, 159
hereditary conditions and state law in, 202
high-risk insurance pool in, 170
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
Tay-Sachs carrier screening in, 256
Tay-Sachs carrier screening of Orthodox Jews in, 256

Financing
as a factor affecting utilization of CF carrier tests, 20, 25, 27
private, 25, 27, 170-174
public, 25, 169

Finland, frequency of AF508 in, 248

Florida
geneic services funding in, 159
hereditary conditions and state law in, 202
high-risk insurance pool in, 170
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
Tay-Sachs carrier screening in, 256
Tay-Sachs carrier screening of Orthodox Jews in, 256
Food and Drug Administration (FDA)
congressional oversight of, 42-43
genent therapy and approval by, 94
MSAFP and, 119, 144
new CF therapies and approval by, 6, 76
regulation of in vitro diagnostics by, 37, 117
regulation of medical devices by, 37, 116-120
regulatory future of CF mutation test kits and, 37, 118-120
regulatory status of reagents used in CF carrier analysis and, 116
Future 500 companies, assessment of health insurance risk of potential employees by, 30, 42, 192
Fragile X syndrome
genetics of, 87, 265
health insurance difficulties and, 34, 200
prenatal diagnosis and screening for, 265
France
frequency of AF508 in, 248
frequency of AF508 in Brittany (Celtic), 249
frequency of AF508 in Lyon, 249
frequency of AF508 in Paris, 249
frequency of AF508 in Southern, 249
membership in European Concerted Action on Cystic Fibrosis of, 241
French Canadians, Tay-Sachs disease and carrier screening in, 254, 255
Funding
CF carrier screening pilot study, 15-16, 52, 101, 157-158, 160-163
CF-related research, 3-4, 100-103
for ELSI Programs, 5, 55-56
Federal and State genetic services, 25, 52, 53
Human Genome Project, 5, 54
lessons from past carrier screening programs, 15, 263
Future prospects, 43-45, 61
Galton, Francis, 51
Gastrointestinal (GI) system, effect of CF on, 3, 70-71
Gene
CF, 3, 6-9, 91, 92
definition of, 3, 85
Gene therapy
clinical trials under way, 94
percent CFF research budget toward, 103
potential for CF, 5, 6, 76, 94
General Accounting Office (GAO), investigations of FDA medical device regulation by, 120
General practitioner (GP)—United Kingdom
CF carrier screening and involvement of, 233-234, 238, 239, 242
role in genetic services of, 231
GeneScreen, cost of CF mutation analysis by, 39, 216
Genetic analysis
definition used in OTA report of, 4, 50
see also Genetic screening; Genetic testing; Genetic tests
Genetic assays
definition used in OTA report of, 4, 50
see also Genetic screening; Genetic testing; Genetic tests
Genetic counseling
abortion and, 45, 127
avoiding stigmatization with nondirective, 29, 192
CF carrier screening context and, 145-150
communicating risk and, 22, 24, 142-143
compensation for inadequate, 23, 129-131
components of, 22, 126-127
confidentiality and, 22-23, 128-129, 131
cost of post-test, 217
definition used in OTA report of, 4, 50, 153
duties of care for, 22-23, 124-129
health care professionals who perform, 4, 24, 50
increased volume of genetic tests and impact on, 24, 151, 152-155
lessons from past carrier screening programs, 143, 144, 152, 264
need for sufficient and appropriate, 22, 141-144, 149
post-test, 148-149
reimbursement by health insurers for, 28, 179, 180, 181-182
reimbursement under Medicaid for, 28, 182-184
standard for, 22-23, 126-127
see also Genetic services
Genetic counselors
1991 OTA survey of, 21, 24, 33, 62, 121, 123, 141, 145, 148, 149, 150, 151, 153, 154, 180, 199-202
definition used in OTA report of, 4, 50, 152
education and training of, 25, 41, 153
Genetic diseases
ADA and, 34-35, 205-206
approximate number of, 5, 54, 86
health insurers’ attitudes toward, 31, 195-197
see also Carrier status; Genetic information; specific disorders
Genetic information
access to health care and, 29-31, 33, 193-194
use by insurers in rating, 32, 196-197
use by insurers in underwriting, 31-32, 195-196
Genetic screening
1975 NRC report on, 54
1983 report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research on, 45, 52, 54
definition used in OTA report, 4, 50
public health and, 57
reimbursement for, 27, 179
see also Genetic testing
Genetic screening program
OTA definition as applied to CF carrier screening, 4, 50
see also α-thalassemia; β-thalassemia; Sickle cell anemia; Tay-Sachs disease
Genetic services
as a factor affecting utilization of CF carrier tests, 20-23
decline in funding for, 25, 52, 53
ensuring quality of, 22-23, 120-131
Federal funding for, 25, 26, 52, 53, 158-160
impact of CF carrier screening on, 24-25, 60-61, 151, 153
impact of Human Genome Project on, 14-15, 53
in the United Kingdom, 17, 231-233
other funding sources for, 25, 53
reimbursement for, 27-28, 179-184
State funding for, 25, 26, 53
see also Genetic counseling
Genetic testing
definition used in OTA report of, 4, 49-50
see also Genetic screening
Genetic tests
access to health insurance after using, 33, 34, 199-202
definition used in OTA report of, 4,50
health insurers’ attitudes toward, 32, 197-199
public attitudes toward, 20-21, 62-63, 143, 190
see also DNA tests; Genetic screening; Genetic services;
Genetic testing; specific conditions
Genetics
basic principles of, 3,6,7, 85-86
human disease and, 86-87
of α-thalassemia, 260
of β-thalassemia, 260-261
of CF, 3, 6, 8, 90-94
of sickle cell anemia, 258
of Tay-Sachs disease, 254-255
Genetics & IVF Institute
cost of CF mutation analysis at, 39, 216
privately funded pilot study at, 19, 161-162
Georgia
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Germany
frequency of AF508 among Turkish population in, 251
frequency of AF508 in Berlin, 249
frequency of AF508 in former East, 249
frequency of AF508 in former West, 249
membership in European Concerted Action on Cystic Fibrosis of, 241
Great Britain, See United Kingdom
Greece
β-thalassemia carrier screening program in, 262
frequency of AF508 in, 249
membership in European Concerted Action on Cystic Fibrosis of, 241
Orthodox Church and β-thalassemia screening in, 262
sickle cell mutation in, 258
Group Health Association of America, 176
Guy Hospital—London, CF carrier screening pilot program at, 17, 233, 238, 239
H & H Music Co., 194
Hahnemann University, cost of CF mutation analysis at, 39, 216
Hawaii
α-thalassemia carrier screening in, 260
β-thalassemia carrier screening in, 260
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Hereditary Anemia Project of, 260
Medicaid reimbursement for genetic services in, 183
Health care coverage
impact of genetics on access to, 33,34,44, 193-194, 199-202
of U.S. population, 25-26, 169
private financing of, 25, 170-174
public financing of, 25, 169-170
see also Health insurance
Health Care Financing Administration (HCFA)
congressional oversight of, 42
regulatory authority under CLIA of, 36, 112-114
Health insurance
ADA and, 35,206-207
consumer concerns about access to, 29-30, 33, 192, 194, 200-201
ethical considerations of, 193
impact of genetics on access to, 34, 193-194, 199-202
individual, 25, 172, 174
medically underwritten groups and, 25, 172, 174
MBI and individual, 174-176
OTA workshops on genetics and, 276
regulation of, 25, 175
risk and employability, 30, 192
types of, 25, 169-174
see also Financing
Health Insurance Association of America (HIAA), 176, 197
Health insurers
attitude toward carrier status as preexisting conditions of, 31, 195
attitude toward fairness in using genetic tests of, 32-33, 177
attitude toward genetic conditions as preexisting conditions of, 31, 195
attitude toward medical information versus genetic information of, 31, 195
attitude toward option of using genetic information of, 177-178
factors affecting insurability by, 31-32, 195-196
future use of genetic tests by, 32, 197-199
genetic risk factors and attitudes of, 193-197
impact of genetic tests on, 32-33, 178
regulation of, 25, 175
reimbursement of CF carrier tests by, 27, 180-182
reimbursement of genetic counseling by, 28, 182
see also Blue Cross/Blue Shield plans; Commercial health insurers; Health insurance; Health maintenance organizations; Medicaid; Reimbursement; Self-funded employers
Health maintenance organizations (HMOs)
attitude toward carrier status as preexisting conditions of, 31, 195
attitude toward fairness in using genetic tests of, 177
attitude toward genetic conditions as preexisting conditions of, 31, 195
attitude toward medical information versus genetic information of, 31, 195
attitude toward option of using genetic information of, 177-178
demographics of respondents, 176-177
factors affecting insurability by, 31-32, 195-196
future use of genetic tests by, 32, 197-199
impact of genetic tests on, 32-33, 178
regulation of, 25, 171-172
reimbursement for CF carrier tests by, 27, 181
reimbursement of genetic counseling by, 28, 182
structure of, 171
see also Blue Cross/Blue Shield plans; Commercial health insurers; Health insurance; Health insurers
Health Resources and Services Administration, 174-176
Hemophilia, health insurance difficulties and, 34, 200
Hemophilia A
...
Index

293

confidentiality and genetic counseling for, 129
health insurance difficulties and, 34, 200
inheritance pattern of, 88
Hemophilia B, inheritance pattern of, 88
Hispanic Americans
CF carrier frequency in, 14, 145
frequency of CF live births among, 5, 49, 90, 219
see also African Americans; Asian Americans; Caucasian Americans of European descent
History
of CF, 3, 49
of eugenics, 51
of U.S. genetic screening programs, 15, 52
of U.S. legislation related to genetics, 15, 51-52
Hitler, Adolph, 51
Hoffmann-La Roche, Inc.
patent rights for PCR and, 217
See also Roche Biomedical Laboratories; Roche Molecular Systems
Holmes, Justice Oliver Wendell, 51
Hong Kong
α-thalassemia carrier screening in, 260
β-thalassemia carrier screening in, 262-263
House Committee on Energy and Commerce, U.S., iii, 3
House Committee on Science, Space, and Technology, U.S., iii, 3
Howard Hughes Medical Institute (HHMI), CF-related research funded by, 100, 103
HUGA-1—Japan, 100
Human Genome Project
Congress and, 3, 5, 54
cost of, 5, 54
ELSI Programs of, 5, 55-56
impact on genetic services of, 14-15, 53
impact on health care access of, 44, 192
impact of intellectual property protection on, 44, 217
National laboratories and, 98, 100, 193-194
scope of, 54-56
stigmatization and, 29, 189
Hungary, frequency of ΔF508 in, 249
Huntington disease
health insurance difficulties and, 34, 200
inheritance pattern of, 87
ICI 200,800,6,76
Idaho
confidentiality of medical information in, 131
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Illinois
confidentiality of medical information in, 131
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Tay-Sachs carrier screening of Orthodox Jews in, 256
Immunoreactive trypsin (IRT) test
mechanics of, 72-73
newborn screening using, 73
Indian Health Service, 169
Indiana
-genetic services funding in, 159
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
wrongful life claims in, 130
Individuals With Disabilities Education Act of 1990, 202
Inductive screening
as relates to CF carrier status, 148
effect on cost-effectiveness of, 225
Infertility
as a factor in cost-effectiveness, 219, 221
related to CF, 71
Informed consent, role of genetic counseling in, 126-127
Inheritance, modes of, 87-89
Institute of Medical Genetics—Wales, 233
Instrumentation. See Automation
Insurance. See Health insurance; Life insurance
Integrated Genetics
cost of CF mutation analysis by, 39, 216
privately funded pilot study and, 19, 162-163
Intellectual property
impact on costs of DNA-based analyses, 39, 216, 217
issues arising from Human Genome Project, 39, 44, 217
PCR and, 39, 217
Interested parties, CF carrier screening and, 56, 58-61
International Society of Nurses in Genetics, 62, 155, 200
Iowa
-genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
hereditary conditions and state law in, 202
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
Iran, sickle cell mutation in, 258
Ireland, Republic of
frequency of ΔF508 in, 249
membership in European Concerted Action on Cystic Fibrosis of, 241
Israel
frequency of ΔF508 among Arabs in, 250
frequency of ΔF508 among Ashkenazi Jews in, 250
frequency of ΔF508 among Non-Ashkenazi Jews in, 250
frequency of ΔF508 among Sephardic Jews in, 250
frequency of ΔF508 in, 250
membership in European Concerted Action on Cystic Fibrosis of, 241
Tay-Sachs carrier screening of Orthodox Jews in, 256
Tay-Sachs disease and carrier screening in, 255
Italy
-carrier screening pilot study in, 17, 238, 239
frequency of ΔF508 in, 250
frequency of ΔF508 in Campania, 250
frequency of ΔF508 in Central/Southern, 250
frequency of ΔF508 in Northern, 250
frequency of ΔF508 in Rome/Verona, 250
frequency of ΔF508 in Sardinia, 250
membership in European Concerted Action on Cystic Fibrosis of, 241
sickle cell mutation in, 258
Cystic Fibrosis and DNA Tests: Implications of Carrier Screening

Japan
- automation of DNA analysis in, 100
- Tay-Sachs carrier screening in, 255

Johns Hopkins University
- cost of CF mutation analysis at, 39, 216
- NIH-funded pilot study at, 18, 158

Joint Commission on Accreditation of Healthcare Organizations (JCAHO)
- CLIA accreditation and, 36, 113

Joint Subcommittee on the Human Genome—NIH/DOE, 35, 156, 206

Joint Working Group on Ethical, Legal, and Social Issues (ELSI)—NIH/DOE, 35, 156, 206

Kansas
- genetic services funding in, 159
- genetics and public education in, 24, 149
- Medicaid reimbursement for genetic services in, 183

Kentucky
- genetic services funding in, 159
- Medicaid reimbursement for genetic services in, 183

Laboratories. See Clinical laboratories
- Lacrimal glands, effect of CF on, 69
- Lawrence Berkeley Laboratory, 100

Legal considerations, ELSI grants funded that relate to, 55-56
- Legislation, U.S., related to genetic disease, 15, 51-52
- see also specific laws

Liability. See Medical malpractice
- Licensing
- fees for royalty, 39, 216, 217
- of genetic specialists, 23, 120-121
- see also Certification
- Life insurance
- CF and, 176
- confidentiality of genetic test information and, 129
- MIB and, 174-175

Ligase chain reaction (LCR), 97
- Linkage analysis, 98
- Liver, effect of CF on, 71
- Los Alamos National Laboratory, 100

Louisiana
- genetic services funding in, 159
- genetics education, technical assistance, and training funding in, 160
- hereditary conditions and state law in, 202
- mandatory reporting of birth defects in, 128
- Medicaid reimbursement for genetic services in, 183
- Tay-Sachs disease and carrier screening in, 255, 257
- wrongful life claims in, 130

Louisiana French Acadians, Tay-Sachs disease and carrier screening in, 254, 255
- Lung therapy, 73-75
- Lung transplants, 77

Maine
- genetic services funding in, 159
- Medicaid reimbursement for genetic services in, 183
- Medical Liability Demonstration Project of, 125

Malpractice. See Medical malpractice
- Marfan syndrome
- health insurance difficulties and, 34, 200
- inheritance pattern of, 87

Maryland
- genetic services funding in, 159
- genetics education, technical assistance, and training funding in, 160
- hereditary conditions and state law in, 202, 203
- mandatory reporting of birth defects in, 128
- Medicaid reimbursement for genetic services in, 183
- study of risk perception in, 24, 143

Tay-Sachs carrier screening in Baltimore, 255, 256
- Tay-Sachs carrier screening of Orthodox Jews in, 256

Massachusetts
- genetic services funding in, 159
- Medicaid reimbursement for genetic services in, 183
- non-master’s-level counselors and sickle cell programs in, 155

Tay-Sachs carrier screening of Orthodox Jews in, 256
- Master’s-level counselors. See Genetic counselors
- Maternal and Child Health (MCH) Block Grant
- as a focus of congressional options to enhance professional education and training, 41-42
- enactment of, 25, 26, 52, 53
- funding for genetic services under, 25, 26, 53, 158-160

Maternal serum alpha-fetoprotein (MSAFP) levels as indicators for Down syndrome or neural tube defects, 16, 143, 144
- regulatory class of test kits for, 118
- screening and reimbursement under Medicaid, 182-184
- screening for, 144, 151
- test kits and FDA, 118-119
- understanding risks of screening results for, 143

Mayo Medical Laboratories, cost of CF mutation analysis by, 39, 216

McCarran-Ferguson Act of 1945, 175
- McGill, John, 194
- McGann v. H & H Music Co, 194

McGann University, pilot study at, 19, 162

Meckel-Gruber fetus, health insurance difficulties and, 34, 200

Meconium ileus, 69, 71
- Median age of individual with CF, 5, 77, 78
- Median survival of individual with CF current, 5, 6, 77
- effect of cost-effectiveness of, 225

Medicaid
- health care coverage under, 25, 169
- reimbursement for genetic services by, 28, 182-184

Medical aspects, 69-79

Medical Device Amendments of 1976 (MDA) regulation of test kits under, 116-118
- see also Food and Drug Administration, U. S.; Safe Medical Devices Act of 1990

Medical Information Bureau (MIB), individual health insurance and, 174-175

Medical malpractice
- inadequate genetic counseling and, 23, 129-131
- influence of professional society statements on claims of, 21, 123
- standards of care and, 21, 122

Tay-Sachs carrier screening and, 121
wrongful birth claims of, 23, 130, 131
wrongful life claims of, 23, 130-131
see also Standards of care
Medical Research Council (MRC)—United Kingdom
CF carrier screening pilot programs funded by, 17, 233
health services research by, 232
role in CF carrier screening of, 232-233
Medicare
clinical laboratory regulation and, 112, 114
health care coverage under, 25, 169
Mendel, Gregor, iii, 87
Michigan
capital of medical information in, 131
fantastic service funding in, 159
genetics education, technical assistance, and training funding in, 160
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
newborn screening fees as a source of genetic services funding in, 26, 53
Tay-Sachs carrier screening of Orthodox Jews in, 256
Miliary Health Services System (MHS), 170
Minnesota
genetic services funding in, 159
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
Mississippi
disability statute of, 204
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Missouri
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Montana
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Morocco, Tay-Sachs disease in Jews from, 254
Mucus
changes in as an indicator of CF, 5, 69
glandular secretions of, 69
Multiple sclerosis, as covered by the ADA, 205
Multiplex analysis, 98
Mutations
causing CF, 3, 58, 90, 91, 253
commonly used in CF carrier tests, 58, 99, 233, 234, 236, 239
effects of, 9, 87-88
inheritance patterns of, 86-87
RFLP and, 12, 95
types of, 87
see also Cystic fibrosis mutations
National Academy of Sciences, 1975 report on genetic screening of, 54
National Association of Insurance Commissioners Insurance Information and Privacy Protection Model Act, 175
National Cancer Institute, pilot projects for genetic tests and cancer, 157-158
National Center for Education in Maternal and Child Health, as a focus of congressional options to improve public education in genetics, 41
National Center for Human Genome Research (NHGRI)
CF carrier screening pilot studies funded by, 16, 52, 56, 101, 157-158
CF-related research funded by, 102
development of approach for pilot studies by, 156-157
pilot projects for genetic tests and cancer, 157-158
research on stigmatization and genetics funded by, 29, 191
role in initiating and funding CF carrier screening pilot studies by, 16, 52
see also Ethical, Legal, and Social Issues Program—NIH
National Center for Nursing Research (NCNR)
CF carrier screening pilot study funded by, 16, 52, 56
CF-related research funded by, 102
development of approach for pilot studies by, 156-157
National Center for Research Resources
CF-related research funded by, 102
joint ELSI program grant funded by, 55
National Cooley’s Anemia Control Act, 52, 261
National Eye Institute (NEI), CF-related research funded by, 102
National Genetic Diseases Act, 15, 24, 25, 43, 51, 149, 158, 255
National Health Service (NHS)—United Kingdom, 231
National Heart, Lung, and Blood Institute (NHLBI), CF-related research funded by, 101, 102
National Institute of Allergy and Infectious Diseases (NIAID), CF-related research funded by, 102
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), CF-related research funded by, 102
National Institute of Child Health and Human Development (NICHD)
CF carrier screening pilot study funded by, 16, 52, 56, 101, 157-158
CF-related research funded by, 102
development of approach for pilot studies by, 156-157
National Institute of Dental Research (NIDR), CF-related research funded by, 102
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CF-related research funded by, 101, 102
development of approach for pilot studies by, 156-157
National Institute of General Medical Sciences (NIGMS), CF-related research funded by, 102
National Institute of Mental Health (NIMH), CF-related research funded by, 102
National Institute of Neurological Disorders and Stroke (NINDS), CF-related research funded by, 102
National Institutes of Health (NIH)
approval for gene therapy by, 94
CF carrier screening pilot studies funded by, 16, 52, 56, 101, 156-158
CF-related research funded by, 100-101, 102
collaboration with CFF to fund research of, 102, 103
ELSI program of, 5, 16, 55-56
Joint Subcommittee on the Human Genome (DOE) of, 35, 206
Workshop on Population Screening for the Cystic Fibrosis Gene, 21, 146, 150, 155-156, 263
see also specific institutes and centers
National laboratories, U.S., 43, 98, 100
National Research Council (NRC), 1975 report on genetic
screening of, 54
National Science Foundation
as a focus of congressional options to improve public
education in genetics, 41
funding for 1975 NRC report and, 54
funding with NIH of ELSI grants, 55
public education in genetics and, 24, 149
National Sickle Cell Anemia Control Act, 52, 259
National Sickle Cell Anemia, Cooley’s Anemia, Tay-Sachs, and
Genetic Diseases Act (National Genetic Diseases Act), 15, 24, 25, 43, 51, 149, 158, 255
National Society of Genetic Counselors (NSGC), 62, 123, 200, 153, 154
National Tay-Sachs and Allied Diseases Association (NTSAD), 257
Native Americans, health care coverage and, 169
Nebraska
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Negligence. See Medical malpractice
Netherlands, the
frequency of ΔF508 in, 250
membership in European Concerted Action on Cystic Fibrosis of, 241
Neurofibromatosis, health insurance difficulties and, 34, 200
Nevada
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
New Hampshire
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
New Jersey
genetic services funding in, 159
hereditary conditions and state law in, 202
mandatory reporting of birth defects in, 128
Medicaid reimbursement for genetic services in, 183
wrongful life claims in, 130
New Mexico
confidentiality of medical information in, 131
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
New York
α-thalassemia carrier screening in Rochester, 260
attitudes toward abortion of families with CF-affected children in Rochester, 127
β-thalassemia carrier screening in Rochester, 261
genetic services funding in, 159
hereditary conditions and state law in, 202
Medicaid reimbursement for genetic services in, 183
regulation of clinical laboratories by, 36, 114, 115
regulation of DNA-based tests by, 115
Tay-Sachs carrier screening in New York City, 256
New Zealand, membership in European Concerted Action on Cystic Fibrosis of, 241
Newborn screening
for CF, 4, 50, 73
for CF carrier status, 150
in the United Kingdom, 231
State law and, 51
Nixon, President, 51, 259
Non-master’ s-level counselors
NSGC recommendations about, 154
role in genetics, 154-155
use in sickle cell programs, 155
Norms, Jane, 29, 191
North America
correlation of frequency of CF mutations in Europe and, 247
equencies of common CF mutations in, 253
frequency of ΔF508 in, 253
North Carolina
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
North Dakota
confidentiality of medical information in, 131
Medicaid reimbursement for genetic services in, 159
Medicaid reimbursement for genetic services in, 183
Northern Ireland
frequency of ΔF508 in, 252
membership in European Concerted Action on Cystic Fibrosis of, 241
see also United Kingdom
Norway, membership in European Concerted Action on Cystic Fibrosis of, 241
Nurses
1991 OTA survey of, 21, 24, 33, 62, 121, 123, 141, 145, 148, 149, 150, 151, 153, 154, 180, 199-202
Federal support for genetics education of, 41, 155
role in genetics of, 25, 155
Obey, Representative David R., iii, 3
Office of Personnel Management, U. S., 28
Office of Technology Assessment (OTA)
1986 survey of public attitudes by, 20-21, 62-63, 94
1989 survey of Fortune 500 and companies with 1,000 or more employees by, 30, 42, 192
1991 survey of genetic counselors and nurses by, 21, 24, 33, 62, 121, 123, 141, 145, 148, 149, 150, 151, 153, 154, 180, 199-202
congressional issues and options identified by, 40-45
cost-effectiveness analysis by, 38-40, 213-226
number of CF carrier tests in 1992 projected by, 18, 20, 61
scope and organization of this report by, 63
terminology used by, 4, 49-50
Ohio
genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183
Tay-Sachs carrier screening in Akron, 256
Oklahoma
genetic services funding in, 159
genetics education, technical assistance, and training funding in, 160
Medicaid reimbursement for genetic services in, 183
Omnibus Budget Reconciliation Act of 1981, 26, 53, 158
Omnibus Budget Reconciliation Act of 1989, 112
Oregon
confidentiality of medical information in, 131
genetic services funding in, 159

genetics education, technical assistance, and training funding in, 160

hereditary conditions and state law in, 202

Medicaid reimbursement for genetic services in, 183

Pancreas
effect of CF on, 69, 70-71
enzyme replacement therapy related to, 75
insufficiency of enzymes from, 70-71

Participation
cost-effectiveness and assumptions about, 38-40, 218-219, 224
effect on cost-effectiveness of, 40, 224
lessons from past carrier screening programs, 15, 263

Pathology
of CF in gastrointestinal system, 4-5, 70-71
of CF in reproductive system, 71
of CF in respiratory system, 4-5, 69-70
of CF in skeletal system, 72
of CF in sweat glands, 71

Pennsylvania
CF screening of newborns in, 73

genetic services funding in, 159
Medicaid reimbursement for genetic services in, 183

Percutaneous umbilical blood sampling, prenatal analysis using, 147

Permanence Medical Group, Inc., privately funded pilot study at, 19, 162-163

Personnel. See Education; Genetic services; Licensing; Training

Pharmaceuticals
costs of CF-related, 38, 215
used to treat CF, 73-74, 75

Phenylketonuria
1975 report of the NRC, 54
1983 report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and, 54
health insurance difficulties and, 34,200
inheritance pattern of, 88

Physical therapy. See Chest physical therapy

Pilot studies
congressional options to facilitate future, 43
federally funded, 16, 18,52, 101, 157-158, 163
in the United Kingdom, 17, 233-239
NIH development of, 156-157
privately funded, 16, 19, 160-163

Planned Parenthood of Southeastern Pennsylvania v. Casey, 45, 127

Poland
frequency of AF508 in, 251
membership in European Concerted Action on Cystic Fibrosis of, 241

Polymerase chain reaction (PCR)
DNA amplification using, 12,95,96,97
intellectual property protection and, 39, 44, 217
quality assurance and, 111

Population carrier screening. See Cystic fibrosis carrier screening; Population target

Population target
cost-effectiveness and assumptions about, 39-40, 218, 219
effect on cost-effectiveness of, 224
lessons from past carrier screening programs, 15,263-264
potential and Likely, 16,58, 150-152
variation among CF carrier screening pilot studies, 15-16, 18, 19, 157-158, 160-162
variation among U.K. CF carrier screening pilot studies, 17, 238,239, 242

Portugal
frequency of AF508 in, 251
membership in European Concerted Action on Cystic Fibrosis of, 241

Practice standards
alternative approach in Maine to set, 125
congressional role in setting, 43
role of Agency for Health Care Policy and Research, 43
see also Standards of care

Preexisting conditions
genetic conditions as, 31, 195
carrier status as, 31, 195
Preferred provider organization (PPO), 170, 171

Pregnancy
CF mutation analysis and, 16, 151
stigmatization of, 189
see also Prenatal testing

Pregnancy termination. See Abortion

Prenatal testing
anxiety and, 148, 151
CF mutation analysis and, 16,58,60,147-148, 151-152,234, 236
decisions about abortion following, 45, 127,265
health insurers’ economic analysis of, 178-179
reimbursement for CF, 27, 181-182

President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research
1983 report on genetic screening, 52,54,63
1983 report on health care access, 193
principles of confidentiality in 1983 report of, 63, 128-129
value of CF carrier screening and, 45, 213, 226

Prices. See Costs

Privacy. See Confidentiality

Professional capacity, impact of increased number of genetic tests on, 24-25, 152-155

Professional societies
interest in CF carrier screening of, 21, 56
policy statements on CF carrier screening of, 123
role in clinical laboratory quality assurance of, 36, 111, 114-116
role in genetic services quality assurance of, 23, 121-122, 123

Proficiency testing, 113, 115-116

Prognosis
current, 77-78

genotypic correlation with, 91
nutritional status and, 5, 71
respiratory difficulties and, 4-5, 69-70, 71

Program
for α-thalassemia carrier screening, 260
for β-thalassemia carrier screening, 261-263
for sickle cell anemia screening, 155,258-259
for Tay-Sachs disease carrier screening, 231,255-257
OTA definition as applied to CF carrier screening, 4,50

Proteins, 86

Public attitudes, toward genetic tests, 20-21,62-63, 143, 190
Public education
as a factor affecting utilization of CF carrier tests, 20, 24
importance for avoiding stigmatization, 15, 29, 149-150, 163, 192
lessons from past carrier screening programs, 15, 24, 152, 264
see also Education

Public health
genetic screening and, 43, 57
professionals and genetic services, 25, 155

Public Health Service Act
Title VII as a focus of congressional options to enhance
professional education and training, 42
Title VIII as a focus of congressional options to enhance
professional education and training, 42
Title X, 45, 127

Public opinion. See Public attitudes
Puerto Rico, genetic services funding in, 159

Quality assurance
as a factor affecting utilization of CF carrier tests, 20, 35-37
of clinical laboratories, 35-37, 111-116
of DNA test kits, 37, 111, 116-120
of genetic services, 22-23, 111, 120-132
see also Clinical Laboratory Improvement Amendments of 1988; Food and Drug Administration, U. S.; Genetic services
Quality control, 111

Recombinant DNA Advisory Committee (RAC)—NIH, 94

Regulation
of BC/BS plans, 25, 171
of clinical laboratories, 35-37, 111-116
of HMOs, 25, 171-172
of insurance contracts, 175
of insuring entities, 25, 175
of medical devices, 37, 116-120
of self-funded employee benefit plans, 27, 171
Rehabilitation Act of 1973, 204

Reimbursement
CF carrier tests and health insurers’ approaches to, 27, 179-182
experience of genetic counselors and nurses with, 180
for CF carrier tests and willingness to be screened, 27, 180, 181-182
genetic services and Medicaid, 28, 182-184
private sector, 27-28, 179-182
public sector, 28, 182-184
see also Financing

Replication
DNA, 85-86, 88
PCR and, 97

Reproductive decisionmaking
as fundamental value of CF carrier screening, iii, 45, 54
cost-effectiveness and assumptions about, 39-40, 219-220
effect on cost-effectiveness of, 40, 223-224
Reproductive system, effect of CF on, 71

Research
CFF and, 102-103
finding for CF-related basic, 3-4, 100-103
Howard Hughes Medical Institute, 100, 103
related to clinical assessments of CF carrier screening, 15-16, 18, 19, 52, 101, 156-158, 160-162
see also United Kingdom screening
definition used in OTA report of genetic, 4, 50
see also β-thalassemia; Cystic fibrosis carrier screening; Cystic fibrosis carrier testing; Sickle cell anemia; Tay-Sachs disease; Testing
Secretory leukocyte protease inhibitor, 76
Self-funded employers
  assessment of health insurance risk of potential employees by, 192
  exemption from contributing to high-risk pools for, 170
  exemption from State insurance regulation under, 27, 171
  health benefit plans of, 171
  health care benefit changes and, 27, 194
  see also Employee Retirement Income Security Act of 1974
Sensitivity
  cost-effectiveness and assumptions about test, 218
  effect on cost-effectiveness of test, 224, 225
  of CF mutation analysis, 10, 13, 58-59
Sequencing. See DNA sequencing
Serous glands, increased salt content in secretions of, 69
Sickle cell anemia
  1983 report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and, 54
  congressional interest in, 51-52, 259
  genetics of, 15, 88, 257, 258
  manifestations of, 257-258
  screening programs for, 15, 155, 258-259
  State laws on, 202, 258-259
  stigmatization and screening for, 192, 259
Single-gene counselors. See Non-master’s-level counselors
Skeletal system, effect of CF on, 72
Social Security Act, Title V of the, 158
Social workers, role in genetic services of, 25, 155
South Africa
  membership in European Concerted Action on Cystic Fibrosis of, 241
  Tay-Sachs carrier screening in, 255
South Carolina
  genetic services funding in, 159
  Medicaid reimbursement for genetic services in, 183
South Dakota
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  Medicaid reimbursement for genetic services in, 183
Southeast Asians
  α-thalassemia and stillbirths among, 260
  α-thalassemia screening in U. S., 260
  β-thalassemia carrier screening of, 262-263
  β-thalassemia mutations in U. S., 259
Southern blot, 95, 96
Southern transfer, 95, 96, 98
Spain
  frequency of AF508 in, 251
  frequency of AF508 in Balearic Islands, 251
  frequency of AF508 in Basque country, 251
  frequency of AF508 in Canary Islands, 251
  frequency of AF508 in Central/Southern, 251
  membership in European Concerted Action on Cystic Fibrosis of, 241
Special Projects of Regional and National Significance (SPRANS), 26, 53, 160
St. Bartholomew’s Hospital (Bart’s)—London, CF carrier screening pilot program at, 17, 238, 239
St. Mary’s Hospital Medical School—London
  CF carrier screening pilot program at, 17, 238-239
  MRC funding for CF carrier screening pilot program at, 233
St. Vincent’s Medical Center, cost of CF mutation analysis at, 39, 216
Standards of care
  alternative approach in Maine to set, 125
  as a factor affecting utilization of CF carrier tests, 20-23
  congressional options for, 40, 43
  factors affecting, 21, 121-124
  medical malpractice and, 21, 122
  professional societies and, 21, 123
States
  abortion laws and, 45, 127
  confidentiality of genetic information and, 22, 128, 131
  eugenics laws and, 51
  funding for genetic services by, 26, 52, 53, 158-160
  hereditary conditions and laws of, 202
  high-risk insurance pools and, 25, 169, 170
  licensing of genetics personnel by, 23, 120
  Medicaid programs of, 25, 169
  Medicaid reimbursement for genetic procedures by, 28, 182-184
  newborn screening laws of, 51
  regulation of health insurance by, 25, 171, 172, 175
  role in quality assurance for clinical laboratories of, 36, 113, 114
  wrongful birth and wrongful life claims in, 23, 130
  see also individual States
Stigmatization
  as a factor affecting utilization of CF carrier tests, 28-35
  avoiding, 29, 192
  concerns stemming from CF carrier screening, 28, 60, 189-191
  empirical studies of genetic, 29, 191-192
  genetic screening and, 52
  of carrier status, 28-29, 189-192
  of pregnancy, 16, 189
  reproductive-related, 28, 190-191
  sickle cell screening and, 259
  Tay-Sachs carrier screening and, 190, 191
  see also Discrimination
Strategies. See Population target
Supreme Court, U.S.
  McCann v. H & H Music Co., 194
  Planned Parenthood of Southeastern Pennsylvania v. Casey, 45, 127
  Roe v. Wade, 45, 127
  Rust v. Sullivan, 45, 127
Survey
  by OTA of American public attitudes toward genetic tests and gene therapy, 20, 62-63, 94
  by OTA of Fortune 500 companies of other employers, 30, 42, 192
  by OTA of genetic counselors and nurses in genetics, 21, 24, 33, 62, 121, 123, 141, 145, 148, 149, 150, 151, 153, 154, 180, 199-202
  by OTA of health insurers, 26-33, 62, 176-180, 193-199
Survival, 77-78
Sweat glands, effect of CF on, 69, 71
Sweat test, 4, 72
Sweden, membership in European Concerted Action on Cystic
Fibrosis of, 241
Switzerland
frequency of ΔF508 in, 251
membership in European Concerted Action on Cystic Fibrosis
of, 241

Target population. See Population target
Tay-Sachs disease
1983 report of the President’s Commission for the Study of
Ethical Problems in Medicine and Biomedical and
Behavioral Research and, 54
California court ruling and standard of care for carrier
screening of, 121-122
carrier frequency of, 121
carrier screening for, 15, 231, 255-257
congressional interest in, 52
genetics of, 15,88,254-255
manifestations of, 254
State law against disc
rumination for, 202
stigmatization and carriers for, 190, 191
Tennessee
genetic services funding in, 159
genetics education, technical assistance, and training funding
in, 160
Medicaid reimbursement for genetic services in, 183
Tay-Sachs carrier screening of Orthodox Jews in, 256
Terminology, used in OTA report, 4,49-50
Test kits
congressional options for regulation of, 40, 42-43
importance to CF carrier screening of, 37, 132
regulatory future of CF mutation, 37, 118-120, 132
Testing
definition used in OTA report of genetic, 4,49-50
see also β-thalassemia; Cystic fibrosis carrier screening;
Cystic fibrosis carrier testing; Screening; Sickle cell
anemia; Tay-Sachs disease
Tests
automation of, 37-38, 98-100
CF functional tests, 9,93
to detect CF mutations, 9-11,58-59, 95-100
to detect genetic disorders, 85
to diagnosis CF, 72-73
Texas
genetic services funding in, 159
McGann v. H & H Music Co., 194
Medicaid reimbursement for genetic services in, 183
Thalassemia. See α-thalassemia; β-thalassemia
Therapy
costs of, 38, 214-216
current CF, 5, 73-77
future CF, 6,76,93
impact in improvements on cost-effectiveness of new, 213,
225
see also Gene therapy; Prognosis; Treatment
Training
as a factor affecting utilization of CF carrier tests, 20, 24-25
congressional issues and options for professional education
and, 40,4142
lack of Federal funding for genetic services-related, 25,52
professional continuing education and, 24, 154
SPRANS funding for, 26, 160
see also Education
Transcription, 8,86,89,92
Translation, 8, 86,89,92
Treatment
chest physical therapy, 5, 76
costs of, 38, 214-216
digestive therapy, 75
effect on cost-effectiveness of costs of, 213
lung therapy, 73-75
transplants, 77
see also Gene therapy; Prognosis; Therapy
Trends
in number of nonresearch carrier tests, 61
in number of research carrier tests, 61
in therapy for CF, 76, 93, 94
in total number of carrier tests, 18, 20, 61
Tuberculosis, compulsory sterilization and, 51
Tulane University, 257
Turkey
frequency of ΔF508 in, 251
sickle cell mutation in, 258
Tunér’s syndrome, health insurance difficulties and, 34,200
Ultrasound, reimbursement under Medicaid for, 28, 182-184
Underwriting, health insurance and, 25-26, 32, 172, 174, 176,
193
Union of Soviet Socialist Republics (USSR; former)
frequency of ΔF508 in, 251
frequency of ΔF508 in Moscow/Odessa, 251
membership in European Concerted Action on Cystic Fibrosis
of, 241
United Kingdom
CF carrier screening in the United States compared to, 17,
241-242
CF carrier screening pilot programs in, 17,233-239
eugenics movement in, 51
Fragile X screening proposed in, 265
frequency of ΔF508 in, 251
frequency of ΔF508 in England, 231,251
frequency of ΔF508 in Northern Ireland, 252
frequency of ΔF508 in Scotland, 231,252
genetic services in, 231-233
MSAFP screening in, 119
outlook for CF carrier screening in, 240-241
public attitudes toward, 17,239
role of CF trust in CF carrier screening, 233-238
role of MRC in CF carrier screening, 232-233
United States
α-thalassemia carrier screening in, 260
β-thalassemia carrier screening in, 261
eugenics movement in, 51
frequency of common CF mutations in, 253
frequency of ΔF508 in, 58,253
sickle cell screening in, 258-259
Tay-Sachs carrier screening in, 255-257
see also Cystic fibrosis; Cystic fibrosis carrier screening;
Federal Government; States
University Hospital of Wales—Cardiff, CF carrier screening
pilot program at, 17,233-234,235,237,239
University of California, Los Angeles (UCLA), School of
Medicine, NIH-funded pilot study at, 18, 158
University of Miami School of Medicine, 256
University of Minnesota, cost of CF mutation analysis at, 39, 216
University of North Carolina
  cost of CF mutation analysis at, 39, 216
  NIH-funded pilot study at, 18, 157
University of Padua—Italy, 238, 239
University of Pennsylvania
  cost of CF mutation analysis at Hospital of, 39, 216
  NIH-funded pilot study at, 18, 158
University of Rochester, NIH-funded pilot study at, 18, 157-158
University of Vienna-Austria, 239
Utah
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  Medicaid reimbursement for genetic services in, 183
Vanderbilt University, NIH-funded pilot study at, 18, 157
Vermont
  genetic services funding in, 159
  Medicaid reimbursement for genetic services in, 183
Virginia
  genetic services funding in, 159
  hereditary conditions and state law in, 202
  mandatory reporting of birth defects in, 128
  Medicaid reimbursement for genetic services in, 183
  sterilization law of, 51
Vivigen, Inc.
  cost of CF mutation analysis by, 39, 216
  privately funded pilot study and, 19, 162-163
Wales
  CF carrier screening pilot program in, 17, 233-234, 235, 237
  membership in European Concerted Action on Cystic Fibrosis of, 241
  see also United Kingdom
Walker Lampley, Bree, 29, 191
Washington
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  mandatory reporting of birth defects in, 128
  Medicaid reimbursement for genetic services in, 183
  wrongful life claims in, 130
West Germany (former).
  See Germany
West Virginia
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  mandatory reporting of birth defects in, 128
  Medicaid reimbursement for genetic services in, 183
Western General Hospital-Edinburgh
  CF carrier screening pilot program at, 17, 233, 234, 236, 238, 239
  MRC funding for CF carrier screening pilot program at, 233
Wisconsin
  CF screening of newborns in, 4, 50, 73, 150
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  hereditary conditions and state law in, 202
  mandatory reporting of birth defects in, 128
  Medicaid reimbursement for genetic services in, 183
World Health Organization, 260, 262
Wrongful birth
  claims and compensation, 23, 130, 131
  definition of, 130
  State statutes on, 130
Wrongful life
  claims and compensation, 23, 130, 131
  definition of, 130
  State statutes on, 130-131
Wyoming
  genetic services funding in, 159
  genetics education, technical assistance, and training funding in, 160
  Medicaid reimbursement for genetic services in, 183
X chromosome
  in females, 85
  in males, 85
  role in Fragile X syndrome, 265
  role in X-linked inheritance, 88, 89, 90
Y chromosome
  genetic disease and, 88
  in males, 85
Yellowstone National Park, 97
Yugoslavia (former)
  frequency of AF508 in, 252
  frequency of AF508 in Macedonia, 252
  frequency of AF508 in Slovenia, 252
  frequency of AF508 in Southern, 252
  membership in European Concerted Action on Cystic Fibrosis of, 241
Other Related OTA Reports

● Artificial Insemination Practice in the United States: Summary of a 1987 Survey
  NTIS order #PB89-139903

● Biotechnology in a Global Economy
  GPO stock # 052-003 -01258-8

● Genetic Monitoring and Screening in the Workplace
  OTA-BA-455, October 1990; 262p.
  NTIS order #PB91-105940

● Genetic Witness: Forensic Uses of DNA Tests
  OTA-BA-438, July 1990; 204p.
  NTIS order #PB90-259110

● Healthy Children.” Investing in Our Future
  NTIS order #PB88-178454

● Human Gene Therapy
  OTA-BP-BA-32, December 1984; 116p,
  NTIS order #PB85-206076

● Infertility.” Medical and Social Choices
  NTIS order #PB88-19&164

● Medical Monitoring and Screening in the Workplace.” Results of a Survey
  GPO stock #052-003-01255-3

● Mapping Our Genes—The Genome Projects: How Big, How Fast?
  OTA-BA-373, A@ 1988; 232p.
  NTIS order #PB88-212402

● Medical Testing and Health Insurance
  NTIS order #PB89-1 16958

● New Developments in Biotechnology: Public Perceptions of Biotechnology
  NTIS order #PB87-207544

● Technologies For Detecting Heritable Mutations in Human Beings
  NTIS order #PB87-140158

NOTE: Reports are available from the U.S. Government Printing Office, Superintendent of Documents, Dept. 33, Washington, DC 20402-9325, (202) 783-3238, and/or the National Technical Information Service, 5285 Port Royal Road, Springfield, VA 22161-0001, (703) 4874650.